EDUCATIONS

2000.02 [Bachelor] Busan National University School of Medicine, Busan, Republic of Korea.

2008.02 [Master] Dong-A University Graduate School of Medicine, Busan, Republic of Korea. (Specialty : Neuro Oncology)

2012.02 [Doctor] Dong-A University Graduate School of Medicine, Busan, Republic of Korea. (Specialty : Neuro Oncology)

POSITION

-2005.02 Resident, Department of Neurosurgery, Dong-A University Medical Center, Busan, Republic of Korea.

-2007.02 Fellowship, Department of Neuro Oncology, National Cancer Center Korea, Goyang, Republic of Korea.

-2013.02 Assistant Professor, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.

Assistant Professor, Sungkyunkwan University Masan Samsung Hospital, Masan, Republic of Korea.

-2014.02 The University of Texas, MD Anderson Cancer Center, Visiting Scholar (Center for Cancer Epigenetics, Department of Molecular and Cellular Oncology)

-2020.02 Associate Professor, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.

Associate Professor, Sungkyunkwan University Samsung Changwon Hospital, Changwon, Republic of Korea.

-2020.02 Vice Dean of Medical School Affair, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea

Director, Department of Human Research and Education, Sungkyunkwan University Masan Samsung Hospital, Masan, Republic of Korea.

-2025.04 (Present) Adjunct Professor, Department of New Biology, Daegu Gyeongbuk Institute Science and Technology (DGIST), Daegu, Republic of Korea.

-2025.04 (Present) Professor, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.

Professor, Sungkyunkwan University Samsung Changwon Hospital, Changwon, Republic of Korea.

• Brain Tumor Surgery in General
• Chemotherapy for Malignant CNS Cancer
• Cancer Epigenetics (Focused on Histone Modification) in Malignant Brain Tumors
• Cancer Metastasis (Focused, Circulating Tumor Cells) of Solid Cancers

• CDKN2A homozygous deletion is a stronger predictor of outcome than IDH-mutation in CNS WHO Grade 4 Gliomas. Biomedicines. 2024; 12, 2256.
• The importance of considering competing risks in recurrence analysis of intracranial meningioma. J Neuro Oncol. 2024; 166(3): 503-511.
• Clinical Application of the Association between Genetic Alteration and Intraoperative Fluorescence Activity of 5-Aminolevulinic Acid during the Resection of Brain Metastasis of Lung Adenocarcinoma. Cancers 2024; 16, 88.
• Fully automated continuous centrifugal microfluidics isolates natural killer cells with high performance and minimal stress. Analytical Chemistry 2023; 95(26): 9949-9958.
• Epigenetic Regulation of the Expression of T Cell Stimulatory and Inhibitory Factors by Histone H3 Lysine Modification Enzymes and Its Prognostic Roles in Glioblastoma. J Kor Med Sci 2023; 38(33): e258.
• Lossless Immunocytochemistry Based on Large-Scale Porous Hydrogel Pellicle for Accurate Rare Cell Analysis. ACS Applied Materials & Interfaces. 2023; 15(12): 15059-15070.
• Nintedanib induces senolytic effect via STAT3 inhibition. Cell Death and Disease. 2022; 13(9): 760.
• Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation. Theranostics. 2022; 12(8): 3676-3689.
• Ki67 index is the most powerful factor for predicting the recurrence in atypical meningioma: retrospective analysis of 99 patients in two institutes. J Kor Neurosurg Soc. 2022; 65(4): 558-571.
• Hypo-trimethylation of histone H3 lysine 4 and hyper-tri/dimethylation of histone H3 lysine 27 as epigenetic markers of poor prognosis in patients with primary central nervous system lymphoma. Cancer Res Treat. 2022; 54(3): 690-708.
• Clinical Outcomes of RTOG 9310 Protocol for Primary Central Nervous System Lymphoma: Single-center experience with 87 Patients. Curr Oncol. 2021; 28; 4655-4672.
• Epigenetic role of histone lysine methyltransferase and demethylase on the expression of transcription factors associated with the epithelial-to-mesenchymal transition of lung adenocarcinoma metastasis to the brain. Cancers 12(12):3632, 2020.
• Postoperative radiotherapy for WHO grade II–III intracranial ependymoma in adults: An intergroup collaborative study (KROG 18-06/KNOG 18-01). Radiat Oncol 150:4-11, 2020.
• A novel cell seeding technology for microarray-based quantitative human primary skeletal muscle cell analysis. Anal Chem 91(22):14214-14219, 2020.
• Microslit on a chip: a simplified filter to capture circulating tumor cells enlarged with microbeads. PLOS One 14(10):e0223193, 2020.

No content available to display!!!

• https://orcid.org/0000-0003-1171-0780